{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T22:06:50Z","timestamp":1766182010173},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This single-arm, prospective, exploratory study investigated the effectiveness of ultra-low-dose radiotherapy in the treatment of ocular adnexal lymphoma (OAL).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and methods<\/jats:title>\n                <jats:p>Patients with pathologically confirmed ocular adnexal low-grade non-Hodgkin lymphoma (predominantly mucosa-associated lymphoid tissue, MALT or follicular lymphoma) were included and treated with ultra-low-dose radiotherapy consisting of 2 successive fractions of 2\u00a0Gy at our institution between 2019 and 2021. Disease response was assessed clinically and radiographically within 4\u00a0months and at 3 to 6-month intervals after treatment. Data collected included rates of overall response, complete response (CR), partial response (PR), lesion size, and acute\/chronic ocular toxic effects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Sixteen patients with median age of 63\u00a0years (range 23\u201386\u00a0years) were included in the study. The histological subtypes included MALT (11 patients; 69%); follicular lymphoma (2 patients; 12%); Lymphoid hyperplasia (3 patient, 19%). At a median follow-up time of 15.5\u00a0months (range 5.0\u201330.0\u00a0months), the overall response rate was 88%, with a CR rate of 75% (n\u2009=\u200912) and a PR rate of 13% (n\u2009=\u20092). The average lesion area was reduced from 117.9\u2009\u00b1\u200960.4 mm<jats:sup>2<\/jats:sup> before radiation therapy to 38.7\u2009\u00b1\u200946.0mm<jats:sup>2<\/jats:sup> at initial evaluation post radiation therapy (<jats:italic>P<\/jats:italic>\u2009=\u20090.002, n\u2009=\u200916), and to 8.5\u2009\u00b1\u200921.2 mm<jats:sup>2<\/jats:sup> (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001 compared with postoperative lesion area) in patients with response at one year (n\u2009=\u200911). Disease progression was noted in 2 patients (12%). The 1-year rates of local progression-free survivals (LPFS) and overall survival (OS) were 85% and 100%, respectively. No distant relapses were observed in any of the patients. No acute or late toxic effects were noted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Ultra\u2013low-dose radiotherapy in patients with OAL is associated with excellent local disease control and long-term survival with no significant acute or late toxicities.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-022-02180-6","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T08:02:49Z","timestamp":1671523369000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Ultra-low-dose radiotherapy in the treatment of ocular adnexal lymphoma: a prospective study"],"prefix":"10.1186","volume":"17","author":[{"given":"Xiaolu","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruonan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochun","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengyu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chungang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinwei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,20]]},"reference":[{"key":"2180_CR1","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/01.pas.0000213350.49767.46","volume":"31","author":"JA Ferry","year":"2007","unstructured":"Ferry JA, Fung CY, Zukerberg L, et al. Lymphoma of the ocular adnexa: a study of 353 cases. Am J Surg Pathol. 2007;31:170\u201384. https:\/\/doi.org\/10.1097\/01.pas.0000213350.49767.46.","journal-title":"Am J Surg Pathol"},{"key":"2180_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/1097-0142(197201)29:1<252-::aidcncr282029013-8>3.0.co;2-#","volume":"29","author":"C Freeman","year":"1972","unstructured":"Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer. 1972;29:252\u201360. https:\/\/doi.org\/10.1002\/1097-0142(197201)29:1%3c252-::aidcncr282029013-8%3e3.0.co;2-#.","journal-title":"Cancer"},{"key":"2180_CR3","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/s0360-3016(03)00767-3","volume":"57","author":"CY Fung","year":"2003","unstructured":"Fung CY, Tarbell NJ, Lucarelli MJ, et al. Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classification subtypes. Int J Radiat Oncol Biol Phys. 2003;57:1382\u201391. https:\/\/doi.org\/10.1016\/s0360-3016(03)00767-3.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2180_CR4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/028418601750288217","volume":"40","author":"K Sasai","year":"2001","unstructured":"Sasai K, Yamabe H, Dodo Y, et al. Non-Hodgkin\u2019s lymphoma of the ocular adnexa. Acta Oncol. 2001;40:485\u201390. https:\/\/doi.org\/10.1080\/028418601750288217.","journal-title":"Acta Oncol"},{"key":"2180_CR5","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1034\/j.1600-0420.-2000.078005547.x","volume":"78","author":"S Johansen","year":"2000","unstructured":"Johansen S, Heegaard S, Bogeskov L, et al. Orbital space-occupying lesions in Denmark 1974\u20131997. Acta Ophthalmol Scand. 2000;78:547\u201352. https:\/\/doi.org\/10.1034\/j.1600-0420.-2000.078005547.x.","journal-title":"Acta Ophthalmol Scand"},{"key":"2180_CR6","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/jnci\/djj248","volume":"98","author":"R Moslehi","year":"2006","unstructured":"Moslehi R, Devesa SS, Schairer C, Fraumeni JF Jr. Rapidly increasing incidence of ocular non-hodgkin lymphoma. J Natl Cancer Inst. 2006;98:936\u20139. https:\/\/doi.org\/10.1093\/jnci\/djj248.","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"2180_CR7","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1136\/bjophthalmol-2019-315637","volume":"105","author":"F Holm","year":"2021","unstructured":"Holm F, Mikkelsen LH, Kamper P, Rasmussen PK, Larsen TS, et al. Ocular adnexal lymphoma in Denmark: a nationwide study of 387 cases from 1980 to 2017. Br J Ophthalmol. 2021;105(7):914\u201320. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-315637.","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"2180_CR8","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.radonc.2008.09.011","volume":"90","author":"H Nam","year":"2009","unstructured":"Nam H, Ahn YC, Kim YD, et al. Prognostic significance of anatomic subsites: results of radiation therapy for 66 patients with localized orbital marginal zone B cell lymphoma. Radiother Oncol. 2009;90(2):236\u201341. https:\/\/doi.org\/10.1016\/j.radonc.2008.09.011.","journal-title":"Radiother Oncol"},{"key":"2180_CR9","doi-asserted-by":"publisher","first-page":"e659","DOI":"10.1016\/j.ijrobp.2011.03.050","volume":"81","author":"JS Goda","year":"2011","unstructured":"Goda JS, Le LW, Lapperriere NJ, et al. Localized orbital mucosa-associated lymphoma tissue lymphoma managed with primary radiation therapy: efficacy and toxicity. Int J Radiat Oncol Biol Phys. 2011;81:e659\u201366. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.03.050.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2180_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13014-020-1477-8","volume":"15","author":"M Niwa","year":"2020","unstructured":"Niwa M, Ishikura S, Tatekawa K, et al. Radiotherapy alone for stage IE ocular adnexal mucosa-associated lymphoid tissue lymphomas: long-term results. Radiat Oncol. 2020;15(1):25. https:\/\/doi.org\/10.1186\/s13014-020-1477-8.","journal-title":"Radiat Oncol"},{"key":"2180_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ophtha.2017.05.037","volume":"125","author":"MT Yen","year":"2018","unstructured":"Yen MT, Bilyk JR, Wladis EJ, et al. Treatments for ocular adnexal lymphoma: a report by the American Academy of Ophthalmology. Ophthalmology. 2018;125:127\u201336. https:\/\/doi.org\/10.1016\/j.ophtha.2017.05.037.","journal-title":"Ophthalmology"},{"issue":"10","key":"2180_CR12","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1097\/IAE.0000000000001026","volume":"36","author":"A Mashayekhi","year":"2016","unstructured":"Mashayekhi A, Hasanreisoglu M, Shields CL, et al. External beam radiation for choroidal lymphoma: efficacy and complications. Retina. 2016;36(10):2006\u201312. https:\/\/doi.org\/10.1097\/IAE.0000000000001026.","journal-title":"Retina"},{"issue":"1","key":"2180_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.radonc.2005.11.005","volume":"78","author":"Y Ejima","year":"2006","unstructured":"Ejima Y, Sasaki R, Okamoto Y, et al. Ocular adnexal mucosa-associated lymphoid tissue lymphoma treated with radiotherapy. Radiother Oncol. 2006;78(1):6\u20139. https:\/\/doi.org\/10.1016\/j.radonc.2005.11.005.","journal-title":"Radiother Oncol"},{"key":"2180_CR14","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.ijrobp.2013.04.035","volume":"86","author":"CE Fasola","year":"2013","unstructured":"Fasola CE, Jones JC, Huang DD, et al. Low-dose radiation therapy (2 Gy\u00d72) in the treatment of orbital lymphoma. Int J Radiat Oncol Biol Phys. 2013;86:930\u20135. https:\/\/doi.org\/10.1016\/j.ijrobp.2013.04.035.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2180_CR15","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s00066-016-0962-3","volume":"192","author":"L K\u00f6nig","year":"2016","unstructured":"K\u00f6nig L, Stade R, Rieber J, et al. Radiotherapy of indolent orbital lymphomas: two radiation concepts. Strahlenther Onkol. 2016;192:414\u201321. https:\/\/doi.org\/10.1007\/s00066-016-0962-3.","journal-title":"Strahlenther Onkol"},{"key":"2180_CR16","doi-asserted-by":"publisher","first-page":"112067211988898","DOI":"10.1177\/1120672119888985","volume":"24","author":"X Yang","year":"2019","unstructured":"Yang X, Dalvin LA, Lim LA, Mashayekhi A, Shields JA, Shields CL. Ultra-low-dose (boom-boom) radiotherapy for choroidal lymphoma in three consecutive cases. Eur J Ophthalmol. 2019;24:1120672119888985. https:\/\/doi.org\/10.1177\/1120672119888985.","journal-title":"Eur J Ophthalmol"},{"issue":"5","key":"2180_CR17","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","volume":"31","author":"JD Cox","year":"1995","unstructured":"Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341\u20136. https:\/\/doi.org\/10.1016\/0360-3016(95)00060-C.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2180_CR18","first-page":"1304","volume-title":"Neoplastic Hematopathology","author":"J Turbiner Geyer","year":"2013","unstructured":"Turbiner Geyer J, Knowles DM. Malignant lymphomas and lymphoid hyperplasias that occur in the ocular adnexa (orbit, conjunctiva and eyelids). In: Knowles DM, editor. Neoplastic Hematopathology. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 1304."},{"key":"2180_CR19","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.ijrobp.2011.03.050","volume":"81","author":"JS Goda","year":"2011","unstructured":"Goda JS, Le LW, Lapperriere NJ, et al. Localized orbital mucosa-associated lymphoma tissue lymphoma managed with primary radiation therapy: efficacy and toxicity. Int J Radiat Oncol Biol Phys. 2011;81:659\u201366. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.03.050.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2180_CR20","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/hed.25738","volume":"39","author":"C Pinnix","year":"2017","unstructured":"Pinnix C, Dabaja B, Milgrom S, et al. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2017;39:1095\u2013100. https:\/\/doi.org\/10.1002\/hed.25738.","journal-title":"Head Neck"},{"key":"2180_CR21","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1200\/JCO.2003.06.085","volume":"21","author":"RW Tsang","year":"2003","unstructured":"Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol. 2003;21:4157\u201364. https:\/\/doi.org\/10.1200\/JCO.2003.06.085.","journal-title":"J Clin Oncol"},{"key":"2180_CR22","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/cncr.11539","volume":"98","author":"T Uno","year":"2003","unstructured":"Uno T, Isobe K, Shikama N, et al. Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa: a multiinstitutional, retrospective review of 50 patients. Cancer. 2003;98:865\u201371. https:\/\/doi.org\/10.1002\/cncr.11539.","journal-title":"Cancer"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02180-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-022-02180-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-022-02180-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T08:06:59Z","timestamp":1671523619000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-022-02180-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,20]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2180"],"URL":"https:\/\/doi.org\/10.1186\/s13014-022-02180-6","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,20]]},"assertion":[{"value":"15 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, and adhered to the tenets of the Declaration of Helsinki (authorization code [2019]72 and approval date Oct.20, 2019). Written informed consent forms were obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to participate"}},{"value":"All authors read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"208"}}